BioFabUSA Logo

Advanced Regenerative Manufacturing Institute

Fast Facts

Established
December 2016
Website armiusa.org
Mission Making practical the scalable, consistent, and cost-effective manufacturing of cell-based products and training the U.S.’s advanced biomanufacturing workforce
Headquarters Manchester, NH
Consortium Organizer Advanced Regenerative Manufacturing Institute (ARMI)
Institute Metrics
 as of September 2025
 
176    Member Organizations
Total Ongoing and Completed Projects
163    Technology Projects
76    Education and Workforce Development (EWD) Projects
Education and Workforce Development
236,000+    Participants in EWD Projects or Institute-led EWD Activities from FY20-FY25
Additional Info
Institute Snapshot
BioFabUSA focuses on developing the standards, tools, and workforce needed to transition tissue and cell-based innovations from research to commercial-scale manufacturing—supporting U.S. leadership in biotechnology and strengthening domestic manufacturing capabilities in a field vital to health, economic, and national security.
 


BioFabUSA's Tissue Foundry
Institute Capabilities
Success Story Examples
  • BioFabUSA, Safi Biotherapeutics, and Sciperio achieved the world's first biomanufacturing of red blood cells in a -40°C environment. BioFabUSA enabled Safi Biotherapeutics to secure private investment and relocate from Europe to BioFabUSA’s campus, scaling production onshore.
     
  • The world’s first scalable, modular, automated platform for biomedical product manufacturing exists thanks to BioFabUSA and industry members DISC and Rockwell Automation. This AI-enabled platform is fueling the expansion of U.S. biomanufacturing capacity.
     
  • BioFabUSA directly supported Miromatrix (United Therapeutics) in creating the world's first life-saving biomanufactured organ alternative for acute liver failure (common after battlefield injuries). This product is rapidly advancing through clinical trials for Warfighters.
     
  • Apprenticeship programs launched by BioFabUSA are building the U.S. biomanufacturing workforce, creating career pathways for American workers and bolstering U.S. competitiveness. Private sector leaders are now adopting these programs.
     
  • BioFabUSA and industry member Regenerative Patch Technologies scaled and automated production of a vision-saving regenerative implant for macular degeneration, a condition affecting 20 million Americans and common after blast injuries. This product is now in clinical trials.